Journals / Klinik Psikofarmakoloji Bülteni / 2006 / Cilt: 16 - Sayı: 1

Neuroleptic malignant syndrome and neuropsychiatric sequelaes: A retrospective study

Nöroleptik malign sendrom ve nöropsikiyatrik sekelleri: Geriye dönük bir araştırma

Pages
31–34
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, some patients may have persistent neuropsychiatric sequelaes which should be taken into account during treatment course and should be dealt with carefully.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to investigate the neuropsychiatric sequelaes that occurred and persisted throughout the follow up period of patients who received a diagnosis of neuroleptic malignant syndrome (NMS).
📊
Key Findings & Data:Method: The records of the 870 patients, who were hospitalized at Psychiatric Hospital of Medical Faculty of Gaziantep University, were evaluated retrospectively for possible diagnosis of NMS.
💡
Conclusion & Impact:However, some patients may have persistent neuropsychiatric sequelaes which should be taken into account during treatment course and should be dealt with carefully.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to investigate the neuropsychiatric sequelaes that occurred and persisted throughout the follow up period of patients who received a diagnosis of neuroleptic malignant syndrome (NMS). Method: The records of the 870 patients, who were hospitalized at Psychiatric Hospital of Medical Faculty of Gaziantep University, were evaluated retrospectively for possible diagnosis of NMS. Ten of 870 inpatients were found to receive a diagnosis of NMS according to DSM-IV criteria during their hospitalization. The treatments and development of any neuropsychiatric sequelae were investigated and noted. Results: Among 10 NMS cases, 4 of them seem to develop neuropsychiatric sequelaes. Two months after development of NMS, in 8 patients, the signs of persisting cog-wheel rigidity and rigidity were observed. During follow-up period of patients, 3 patients presented cognitive deficiency, 1 presented parkinsonism, and 1 patient had flexion-contracture in his hand as a permanent complication of NMS. The cognitive deficiency in case 1 resolved after 4 months which had been presumed to be related with ECT treatment. The symptoms of cognitive deficiencies in other cases did not show any progress despite vigorous treatment. Conclusions: With the development of emergency treatment approaches, NMS cases usually respond to treatment and are mostly improved mortality rates were decreased. However, some patients may have persistent neuropsychiatric sequelaes which should be taken into account during treatment course and should be dealt with carefully.

Özet

Amaç: Bu çalışmada kliniğimizde, nöroleptik malign sendrom (NMS) tanısı konulup takip edilen olguların klinik izlemleri ve sonrasında ortaya çıkan nöropsikiyatrik sekellerinin incelenmesi amaçlanmıştır. Yöntem: Ocak 2001 - Ocak 2006 dönemleri arasında Gaziantep Üniversitesi Tıp Fakültesi Psikiyatri kliniğinde yatarak tedavi gören 870 hastanın dosyası araştırıldı. NMS tanısı konulmuş olan 10 olgunun tıbbi dosyaları geriye dönük olarak incelenmiştir. Olguların tanıları DSM IV tanı ölçütlerine göre konulmuş olup, olgular tedavi ve nöropsikiyatrik sekeller yönünden değerlendirilmiştir. Bulgular: NMS tanısı konulmuş 10 olgunun 4’ünde kalıcı nöropsikiyatrik sekel geliştiği görülmüştür. Sekiz hastada NMS tedavisi sonrası 2 aylık dönem içerisinde devam eden dişli çark, rijidite gibi bulgulara rastlanılmıştır. Hastaların uzun dönem izleminde ise 3 hastada bilişsel kayıp, 1 hastada parkinsonizm ve 1 hastada elde şeksiyon kontraktürü şeklinde kalıcı nöropsikiyatrik sekeller görülmüştür. Olgu 1’de ortaya çıkan bilişsel işlevlerdeki kayıp 4 ay sonra normale dönmüş olup, bilişsel işlev kaybının EKT uygulamasına bağlı olabileceği düşünülmüştür. Diğer iki olguda gelişen bilişsel işlev kaybı kalıcı olmuştur. Sonuç: Acil tedavi yaklaşımlarının geliştirilmesi ile NMS olgularının büyük çoğunluğu iyileşmekte, ölüm oranları azalmaktadır. Bununla birlikte bir kısım hastada kalıcı nöropsikiyatrik sekeller ortaya çıkabilmektedir. Bu çalışma, NMS komplikasyonlarının yalnızca erken dönemle sınırlı olmadığını göstermesi açısından önemlidir.

🔖

Cite This Article

KANDEMİR, H., CANSEL, N., ÖZEN, M. E., SAVAŞ, H. A., YUMRU, M. (2022). Neuroleptic malignant syndrome and neuropsychiatric sequelaes: A retrospective study. Klinik Psikofarmakoloji Bülteni, Cilt: 16 - Sayı: 1, 31–34. https://ajindex.com/articles/574411

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Kaplan HI, Sadock B, Grebb JA. Synopsis of Psychiatry. 8. Baskı,
  2. Baltimore, Williams& Wilkins 1994:953 2. Yüksel N, Köroğlu E. Nöroleptik malign sendrom. Klinik Uygulamalı psikofarmakoloji. Ankara. Hekimler Yayın Birliği 1991:91-97 3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4.baskı,Washington DC, American Psychiatric Association 1994:739-742 4. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998;155:1113-1116 5. Sing KJ, Ramaekers GM, Van Harten PN. Neuroleptic malignant syndrome and quetiapine. Am J Psychiatry 2002;159:149-150 6. Bora E, Gönül AS, Akdeniz F, Vahip S. Neuroleptic malignant-like" syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. European Psychiatry 2003;18:322-323 7. Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986;73:337-347 8. Gelder MG, Gath D, Mayou R. The Neuroleptic Malignant Syndrome'. Oxford Texbook of Psychiatry, Third edition, Oxford University Pres 1996:554-555 9. Ingall TJ, Tennant C. Neuroleptic malignant syndrome. Med J Aust 1986;145:454-455 10. Adityanjee, Sajatovic M, Munshi KR. Neuropsychiatric Sequelae of Neuroleptic Malignant Syndrome. Clin Neuropharmacol 2005;28:197-204 11. Allstop P, Twigley Aj. The neuroleptic malignant syndrome. Anaesthesia 1987:42:49-53 12. Yumru M, Savaş HA, Savaş E. Tek Doz Klorpromazin Uygulaması Sonrası Gelişen ve Elektrokonvulsif Tedaviye Olumlu Yarat Veren Nöroleptik Malign Sendrom: Olgu Sunumu. Türkiye'de Psikiyatri 2005:7:126-128 13. Özen ME, Yumru M, Herken H, Savaş HA. Ziprasidon Tedavisinin ikinci Gününde Gelişen Nöroleptik Malign Sendrom: Olgu Sunumu. 41.Ulusal Psikiyatri Kongresi Bildiri Kitabı 2005:210 14. Koponen H, Repo E, Lepola U. Long-term outcome after neuroleptic malignant syndrome. Acta Psychiatr Scand 1991:84:550-551 15. Black KJ, Racette B, Perlmutter JS. Preventing contractures in neuroleptic malignant syndrome and dystonia. Am J Psychiatry 1998:155:1298-1299 16. Craddock B, Craddock N. Contractures in neuroleptic malignant syndrome. Am J Psychiatry 1997;154;436 17. Buckley P, Freyne A, McCarthy A, Larkin C. Neuroleptic malignant syndrome follow-up study. Ir J Med Sci 199T;160:45-47 18. Lee S, Merriam A, Kim TS, Liebling M, Dickson DW, Moore GR. Cerebellar degeneration in neuroleptic malignant syndrome: neuropathologic findings and review of the literature conce